Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 1:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–37 of 37 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Enanta Pharmaceuticals, Inc Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Safety and Pharmacokinetics of a Single Oral Dose of EDP-788

NCT01999725
View directory record Official record
Conditions
Safety in Normal Volunteers
Interventions
EDP-788, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 45 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 9, 2015 · Synced Oct 11, 2026, 1:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Multiple Ascending-Dose Study of EDP 322 in Healthy Adult Volunteers

NCT00990145
View directory record Official record
Conditions
MRSA, SSTI
Interventions
EDP-322
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 45 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2009 · Synced Oct 11, 2026, 1:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics of Ascending Single Oral Doses of EDP-322 in Nonfasting and Fasting Healthy Volunteers

NCT00989872
View directory record Official record
Conditions
Skin and Soft Tissue Infections, Methicillin-resistant Staphylococcus Aureus
Interventions
EDP-322
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 45 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2009 · Synced Oct 11, 2026, 1:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Absorption, Metabolism, and Excretion (AME) Study of [14C]EDP-938 in Healthy Male Subjects

NCT04927793
View directory record Official record
Conditions
Respiratory Syncytial Virus (RSV)
Interventions
EDP-938
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 23, 2022 · Synced Oct 11, 2026, 1:24 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of EDP-788

NCT02255968
View directory record Official record
Conditions
Healthy
Interventions
EDP-788, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 12, 2015 · Synced Oct 11, 2026, 1:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study Between Fluconazole and EDP-938 in Healthy Subjects

NCT04871724
View directory record Official record
Conditions
RSV Infection
Interventions
EDP-938, Fluconazole
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Oct 11, 2026, 1:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Absorption, Metabolism and Excretion (AME) Study of [14C]EDP-305 in Healthy Male Subjects

NCT03748628
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
EDP-305
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 21, 2018 · Synced Oct 11, 2026, 1:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction Study Between EDP-305, Intraconazole and Rifampin in Healthy Volunteers

NCT03213145
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
intraconazole, Rifampin, EDP 305
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 11, 2026, 1:24 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis

NCT03394924
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
EDP-305 1 mg, EDP-305 2.5 mg, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
40
States / cities
Dothan, Alabama • Little Rock, Arkansas • Coronado, California + 28 more
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Oct 11, 2026, 1:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323.

NCT06847464
View directory record Official record
Conditions
RSV Infection, Drug Drug Interaction (DDI)
Interventions
EDP-323, Itraconazole, carbamazepine, Quinidine, fluconazole
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Oct 11, 2026, 1:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of EDP-235 in Healthy Subjects

NCT05246878
View directory record Official record
Conditions
SARS CoV 2 Infection
Interventions
EDP-235, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2022 · Synced Oct 11, 2026, 1:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study Between EDP-938, Cyclosporine and Prednisone in Healthy Adult Subjects

NCT03750383
View directory record Official record
Conditions
RSV Infection
Interventions
EDP-938, Cyclosporine, Prednisone
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2019 · Synced Oct 11, 2026, 1:24 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate EDP 938 Regimens in Children With RSV

NCT04816721
View directory record Official record
Conditions
Respiratory Syncytial Virus (RSV)
Interventions
EDP-938, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
28 Days to 36 Months
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
16
States / cities
Long Beach, California • Los Angeles, California • Sacramento, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Oct 11, 2026, 1:24 PM EDT